{"id":6030,"date":"2026-06-24T16:38:08","date_gmt":"2026-06-24T16:38:08","guid":{"rendered":"https:\/\/regenerated.health\/tesamorelin-visceral-fat\/"},"modified":"2026-06-24T17:38:19","modified_gmt":"2026-06-24T17:38:19","slug":"tesamorelin-visceral-fat","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/tesamorelin-visceral-fat\/","title":{"rendered":"Tesamorelin for Visceral Fat: Evidence and What to Expect"},"content":{"rendered":"

The short answer:<\/strong> Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that signals the pituitary to release more of your own growth hormone, which in turn raises IGF-1 and helps the body break down visceral fat. It is the one GH-axis peptide with real clinical evidence for reducing deep abdominal fat, and it is FDA approved for a specific group: adults with HIV-associated lipodystrophy who carry excess visceral fat. Outside that indication, interest is growing but the evidence is thinner. It is a daily subcutaneous injection that requires medical supervision and ongoing monitoring of blood sugar and IGF-1.<\/p>\n

What tesamorelin is<\/h2>\n

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus normally uses to tell the pituitary gland to secrete growth hormone. It is sold under the brand name Egrifta (more recently as Egrifta SV and Egrifta WR). Because it works upstream of growth hormone rather than replacing it directly, it preserves the body’s natural pulsing rhythm of GH release instead of flooding the system with a flat dose.<\/p>\n

That distinction matters. Tesamorelin belongs to the same broad family as sermorelin<\/a> and other GHRH-based compounds, but it stands apart for one reason: it has been studied in large, placebo-controlled human trials with a hard clinical endpoint, namely the amount of visceral fat measured on imaging. Most peptides in this space cannot say that.<\/p>\n

How it works on visceral fat<\/h2>\n

Visceral adipose tissue (VAT) is the fat packed around the organs inside the abdomen. It is metabolically active in unhelpful ways and is linked to insulin resistance, inflammation, and cardiovascular risk. It behaves differently from the subcutaneous fat you can pinch.<\/p>\n

By raising growth hormone and downstream IGF-1, tesamorelin promotes lipolysis, the breakdown of stored fat, with a preferential effect on visceral fat. The result in trials is a measurable shrinking of the deep abdominal fat depot rather than broad weight loss. People often see their waistline change without the scale moving dramatically, because the drug is redistributing and reducing a specific fat compartment rather than driving large overall calorie deficits.<\/p>\n

The approved use and the trial evidence<\/h2>\n

Tesamorelin was first FDA approved in 2010 for the reduction of excess visceral abdominal fat in adults with HIV who have lipodystrophy. Lipodystrophy is a pattern of abnormal fat distribution that some people with HIV develop, partly linked to older antiretroviral therapies, and the visceral fat accumulation can be both physically uncomfortable and metabolically harmful.<\/p>\n

In the pivotal trials, adults given 2 mg subcutaneously once daily for about 26 weeks saw a meaningful reduction in CT-measured visceral fat compared with placebo. Reported average reductions in visceral adipose tissue have been in the range of roughly 15 to 18 percent over six months, with regain when treatment stopped. There is also evidence from a randomized trial that tesamorelin can reduce liver fat in HIV patients with abdominal fat accumulation. These are the strongest data behind any GH-axis peptide for visceral fat, which is why tesamorelin is the reference point in this category.<\/p>\n

A practical note from the trials: the visceral fat tends to return after the drug is discontinued, which tells you this is an ongoing therapy rather than a one-time fix.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
At a glance<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Drug class<\/td>\nGHRH analog (raises GH and IGF-1)<\/td>\n<\/tr>\n
FDA-approved use<\/td>\nExcess visceral abdominal fat in adults with HIV-associated lipodystrophy<\/td>\n<\/tr>\n
Typical studied dose<\/td>\n2 mg subcutaneous, once daily<\/td>\n<\/tr>\n
Time to effect<\/td>\nVisceral fat changes measured over ~26 weeks<\/td>\n<\/tr>\n
Approx. VAT reduction<\/td>\nRoughly 15 to 18 percent in HIV trials over 6 months<\/td>\n<\/tr>\n
After stopping<\/td>\nVisceral fat tends to return<\/td>\n<\/tr>\n
Supervision<\/td>\nPrescription only; requires monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Off-label interest<\/h2>\n

Because visceral fat is a problem far beyond the HIV population, tesamorelin has attracted off-label interest for general visceral fat reduction, metabolic health, and as part of broader peptide therapy<\/a> protocols. Some clinicians prescribe it for people without HIV who carry excess abdominal fat or have related metabolic concerns.<\/p>\n

It is worth being honest here. The robust trial evidence sits in the HIV-associated lipodystrophy setting. Use outside that population is far less studied, and we do not have the same quality of long-term safety and efficacy data for, say, an otherwise healthy middle-aged adult using it purely for body composition. That does not mean it cannot work in those contexts, but it does mean expectations should be measured and the decision should be made with a knowledgeable prescriber who can weigh the unknowns.<\/p>\n

How it is taken<\/h2>\n

Tesamorelin is given as a subcutaneous injection. The original and most-studied regimen is a daily injection, typically reconstituted from a powder shortly before use. A newer formulation (Egrifta WR) has been approved with the goal of reducing the preparation burden and improving adherence, since daily reconstitution and injecting is a real-world hurdle for many people.<\/p>\n

It is not a pill, and it is not something to start casually from an unregulated source. Sterility, correct dosing, and proper storage all matter, which is another reason this belongs under clinical supervision rather than self-directed experimentation.<\/p>\n

Side effects and what to monitor<\/h2>\n

The side effects of tesamorelin flow largely from raising growth hormone activity. The most commonly reported include:<\/p>\n